Want to see IN:KREBSBIO full AI Analyst Report?
KREBSBIO Stock Chart & Stats
₹71.00
-₹2.80(-2.89%)
At close: 4:00 PM EST
₹71.00
-₹2.80(-2.89%)
Day’s Range― - ―
52-Week Range₹38.52 - ₹81.80
Previous CloseN/A
Volume3.29K
Average Volume (3M)726.00
Market Cap
₹1.18B
Enterprise Value₹3.71K
Total Cash (Recent Filing)₹1.29M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta1.41
Next Earnings
Nov 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.54
Shares Outstanding21,560,587
10 Day Avg. Volume346
30 Day Avg. Volume726
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)-0.53
Price to Sales (P/S)3.61
P/FCF Ratio-7.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Gross Margin RecoveryThe return to positive gross margin indicates improved product economics or input-cost absorption. If sustained through higher utilization and disciplined pricing, it could support future operating recovery, although profitability has not yet returned.
Improving Free Cash Flow TrendYear-over-year improvement in free cash flow suggests cash losses may be narrowing from the prior period. Sustained improvement would strengthen funding flexibility, though the company still requires a material reduction in cash burn.
Reported EPS GrowthReported EPS growth provides a limited positive signal that per-share performance improved over the comparison period. Its durability remains uncertain because the company still reports substantial net losses and negative equity.
Bears Say
Negative Equity And Heavy LeveragePersistent negative equity and substantial leverage weaken balance-sheet resilience and increase refinancing and solvency risk. These constraints can limit investment, supplier confidence, and the company’s ability to absorb further operating losses.
Persistent Losses And Shrinking RevenueRecurring operating and net losses, combined with multi-year revenue contraction, indicate weak underlying demand or execution. The latest net margin of about -71% shows that the gross-margin recovery has not translated into a viable earnings model.
Ongoing Cash BurnSustained negative operating and free cash flow means the business is not internally funding its activities. Continued cash burn can increase dependence on borrowing or external capital, especially given the already stressed balance sheet.
Krebs Biochemicals & Industries Ltd. News
KREBSBIO FAQ
What was Krebs Biochemicals & Industries Ltd.’s price range in the past 12 months?
Krebs Biochemicals & Industries Ltd. lowest stock price was ₹38.52 and its highest was ₹81.80 in the past 12 months.
What is Krebs Biochemicals & Industries Ltd.’s market cap?
Krebs Biochemicals & Industries Ltd.’s market cap is ₹1.18B.
When is Krebs Biochemicals & Industries Ltd.’s upcoming earnings report date?
Krebs Biochemicals & Industries Ltd.’s upcoming earnings report date is Nov 10, 2026 which is in 74 days.
How were Krebs Biochemicals & Industries Ltd.’s earnings last quarter?
Krebs Biochemicals & Industries Ltd. released its earnings results on Aug 07, 2026. The company reported -₹1.152 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Krebs Biochemicals & Industries Ltd. overvalued?
According to Wall Street analysts Krebs Biochemicals & Industries Ltd.’s price is currently Overvalued.
Does Krebs Biochemicals & Industries Ltd. pay dividends?
Krebs Biochemicals & Industries Ltd. does not currently pay dividends.
What is Krebs Biochemicals & Industries Ltd.’s EPS estimate?
Krebs Biochemicals & Industries Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Krebs Biochemicals & Industries Ltd. have?
Krebs Biochemicals & Industries Ltd. has 21,560,587 shares outstanding.
What happened to Krebs Biochemicals & Industries Ltd.’s price movement after its last earnings report?
Krebs Biochemicals & Industries Ltd. reported an EPS of -₹1.152 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.029%.
Which hedge fund is a major shareholder of Krebs Biochemicals & Industries Ltd.?
Currently, no hedge funds are holding shares in IN:KREBSBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Krebs Biochemicals & Industries Ltd.
Established in 1991 and headquartered in Hyderabad, India, Krebs Biochemicals & Industries Limited primarily focuses on the production and distribution of active pharmaceutical ingredients (APIs) across India. The company also innovates by developing biotechnological processes applicable to the medical, agricultural, and industrial sectors. Its current portfolio includes compounds like androstenedione, lovastatin, and simvastatin, which serve as steroid intermediates and anti-cholesterol agents. Furthermore, Krebs Biochemicals is actively developing new products such as amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine, targeting diverse therapeutic applications including anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough relief. The firm also extends its expertise by offering contract manufacturing services to large pharmaceutical and multinational corporations.
Technical Analysis
Alpa Laboratories Limited
―
Bal Pharma Limited
―
Biofil Chemicals & Pharmaceuticals Ltd.
―
Par Drugs and Chemicals Limited
―
Vivimed Labs Limited
―